| |
Total
|
EPD +
|
EPD-
|
p-value
|
|---|
|
Number of patients
|
73
|
31
|
42
| |
|
Age (years)
|
64.5 ± 6 (51–78)
|
66.3 ± 5.4 (53–76)
|
63.2 ± 6.2 (51–78)
|
0.026
|
|
PSA before PET/MRI (ng/ml)
|
14.4 ± 17.1 (1.2–104)
|
22 ± 20 (2.1–104)
|
10.3 ± 10.2 (1.22–55)
|
0.031
|
|
MRI (n)
|
|
Internal–external
|
55–18
|
18–13
|
37–5
| |
|
1.5–3.0 T
|
2–71
|
1–30
|
1–41
| |
|
Endorectal coil–No coil
|
8–65
|
6–25
|
2–40
| |
|
Time between mpMRI and PET
|
|
Days
|
64.6 ± 50.5 (0–175)
|
65.5 ± 48.1 (0–174)
|
63.9 ± 52.2 (0–175)
|
0.729
|
|
Clinical T stage (n)
| |
0.052
| | |
|
T1
|
46/73 (63%)
|
16/31 (52%)
|
30/42 (71.5%)
| |
|
T2
|
24/73 (32.5%)
|
12/31 (38.5%)
|
12/42 (28.5%)
| |
|
T3
|
2/73 (3%)
|
2/31(6.5%)
|
0/42 (0%)
| |
|
T4
|
1/73 (1.5%)
|
1/31 (3%)
|
0/42 (0%)
| |
|
ISUP biopsy grade n (%)
| |
0.220
| | |
|
1
|
2/73 (3%)
|
0/31 (0%)
|
2/42 (5%)
| |
|
2
|
10/73 (14%)
|
6/31 (19.5%)
|
4/42 (10%)
| |
|
3
|
15/73 (20%)
|
4/31 (13%)
|
11/42 (26%)
| |
|
4
|
30/73 (41%)
|
10/31 (32%)
|
20/42 (47%)
| |
|
5
|
16/73 (22%)
|
11/31 (35.5%)
|
5/42 (12%)
| |
|
Time between PET and RPE
|
|
Days
|
38.3 ± 31.2 (1–177)
|
36.2 ± 23.2 (3–93)
|
39.9 ± 35.9 (1–177)
|
0.969
|
|
ISUP RPE grade n (%)
| | | |
< 0.001
|
|
1
|
0/73 (0%)
|
0/31 (0%)
|
0/42 (0%)
| |
|
2
|
9/73 (12.5%)
|
3/31 (10%)
|
6/42 (14%)
| |
|
3
|
28/73 (38.5%)
|
5/31 (16%)
|
23/42 (55%)
| |
|
4
|
17/73 (23%)
|
8/31 (26%)
|
9/42 (21%)
| |
|
5
|
19/73 (26%)
|
15/31 (48%)
|
4/42 (10%)
| |
- Statistically significant p-values are marked by bold font
- EPD extraprostatic disease (on RPE specimen); SD standard deviation; mpMRI multiparametric magnetic resonance imaging; PET positron emission tomography/magnetic resonance imaging; PSA prostate-specific antigen; ISUP international society of urological pathology; and RPE radical prostatectomy
